SCHEMBL29562473

SCHEMBL29562473

Cc1c(Oc2cccc(N)c2Cl)ccc([N+](=O)[O-])c1C(=O)OC(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 5/20 0.40
▸ KMT2A Q03164 5/20 0.40
▸ TDP1 Q9NUW8 3/20 0.40
▸ TTR P02766 1/20 0.40
▸ ALB P02768 1/20 0.40
▸ THRB P10828 1/20 0.40
▸ LMNA P02545 5/20 0.38
▸ SMN1; SMN2 Q16637 3/20 0.38
▸ POLB P06746 1/20 0.38
▸ PIN1 Q13526 1/20 0.36
▸ GRM6 O15303 1/20 0.35
▸ HPGD P15428 2/20 0.34
▸ HTT P42858 2/20 0.34
▸ ATM Q13315 1/20 0.34
▸ NR3C2 P08235 1/20 0.34
▸ L3MBTL1 Q9Y468 2/20 0.34
▸ KDM4E B2RXH2 3/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ MAPT P10636 4/20 0.33
▸ HSP90AA1 P07900 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22832045 1.00 MEN1 (0.40) MEN1KMT2ATDP1TTRALB
SCHEMBL22832130 0.88 GRM6 (0.35) MEN1KMT2ATDP1LMNASMN1; SMN2
SCHEMBL29562072 0.88 GRM6 (0.35) MEN1KMT2ATDP1LMNASMN1; SMN2
SCHEMBL22832028 0.83 LMNA (0.36) MEN1KMT2ATDP1TTRALB
SCHEMBL29561773 0.83 LMNA (0.36) MEN1KMT2ATDP1TTRALB
SCHEMBL22831892 0.81 LMNA (0.40) MEN1KMT2ATDP1TTRLMNA
SCHEMBL29562065 0.81 LMNA (0.40) MEN1KMT2ATDP1TTRLMNA
SCHEMBL22831871 0.79 LMNA (0.35) MEN1KMT2ATDP1TTRALB
SCHEMBL29561799 0.79 LMNA (0.35) MEN1KMT2ATDP1TTRALB
SCHEMBL28695162 0.79 TDP1 (0.45) MEN1KMT2ATDP1TTRALB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114026073-B Quinazolin-4-one derivatives for the treatment of BRAF related diseases and disorders ARRAY生物制药公司 2024-08-23 — — CN disclosed
US-11414404-B2 Compounds for the treatment of BRAF-associated diseases and disorders ARRAY BIOPHARMA INC. (US) 2022-08-16 — — US disclosed
EP-3990437-A1 QUINAZOLIN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS Array Biopharma, Inc. (US) 2022-05-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11414404-B2 Compounds for the treatment of BRAF-associated diseases and disorders BRAF, NRAS, RAF1 MEN1 19/4885KMT2A 1743/4885TDP1 652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback